

# Dorota Z Danielak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386259/publications.pdf>

Version: 2024-02-01

21  
papers

363  
citations

933410

10  
h-index

794568

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

594  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 176, 106254.	4.0	3
2	Vortioxetine in management of major depressive disorder – a favorable alternative for elderly patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1167-1177.	1.8	5
3	Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial. <i>Pharmaceutics</i> , 2021, 13, 804.	4.5	4
4	A novel open source tool for ELISA result analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 189, 113415.	2.8	4
5	Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model. <i>Pharmacological Reports</i> , 2020, 72, 1297-1309.	3.3	0
6	Physiologically Based Dissolution Testing in a Drug Development Process – a Case Study of a Successful Application in a Bioequivalence Study of Trazodone ER Formulations Under Fed Conditions. <i>AAPS PharmSciTech</i> , 2020, 21, 161.	3.3	12
7	Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 419-430.	1.9	4
8	Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1105, 113-119.	2.3	13
9	Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 79-89.	1.9	15
10	Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 103-112.	1.8	25
11	Relationship between exposure to treosulfan and its monoepoxytransformer – An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 120, 1-9.	4.0	5
12	Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. <i>Drugs</i> , 2018, 78, 1105-1112.	10.9	30
13	Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 99-107.	1.6	21
14	Development of a Limited Sampling Strategy for the Estimation of Exposure to High-Dose Etoposide After Intravenous Infusion in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 138-144.	2.0	2
15	Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 190-198.	1.2	10
16	Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1623-1632.	1.9	21
17	The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 874-880.	2.0	21
18	Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases. <i>Clinical Pharmacokinetics</i> , 2014, 53, 155-164.	3.5	80

#	ARTICLE	IF	CITATIONS
19	HPCE AND HPLC METHODS FOR DETERMINATION OF CLOPIDOGREL AND ITS CARBOXYLIC ACID METABOLITE IN BIOLOGICAL SAMPLES: A COMPARATIVE ANALYSIS. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2014, 37, 620-633.	1.0	3
20	HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 911, 105-112.	2.3	47
21	Genetic and non-genetic factors affecting the response to clopidogrel therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 663-683.	1.8	38